Precision Neuroscience下注脑表面薄膜而非细线，有望在脑机接口赛道领先——先获FDA批准

做的是什么生意

New York BCI maker developing Layer 7, a hair-thin 1,024-electrode film laid on the brain to record, monitor and stimulate cortical signals — sold first for surgical mapping, aimed at restoring speech and movement for paralyzed people.

启动资金：$102M Series C (Dec 2024, led by General Equity Holdings; B Capital, Duquesne Family Office, Steadview Capital); $155M raised total.

起因

Precision was founded in New York in 2021 by CEO Michael Mager and CSO Benjamin Rapoport, a neurosurgeon-engineer who helped found Neuralink in 2017 and left a year later. Its founding bet inverted the field's slide toward deeper implants: place arrays on the brain's surface, where films can be added without cutting tissue, so resolution can scale.

经过

In April 2024, Mount Sinai surgeons placed four Layer 7 films on one patient — 4,096 electrodes over about 8 cm² — a world record for recording from a human brain, during a benign-tumor surgery where the array mapped motor and sensory boundaries. On 2024-12-16 it closed a $102M Series C led by General Equity Holdings with B Capital, Duquesne Family Office and Steadview Capital, taking total funding to $155M. On 2025-04-16 the FDA gave Layer 7 510(k) clearance — which Precision called the first full regulatory clearance for a wireless BCI — authorizing commercial use with implantation up to 30 days; 37 patients had been implanted by then. By August 2026, nearly 100 participants at 18 US academic centers had used Layer 7 to move cursors, answer video calls and play Mario Kart and Fruit Ninja with thought alone.

可借鉴之处

侵入性更低的设计加上更快的监管路径可以击败更引人注目的方案：Precision利用FDA批准的表面薄膜收集数据和收入，而细线竞品仍处于试验阶段。